Cite

HARVARD Citation

    Jurczak, W. et al. (2021). Phase I, first-in-human trial of Bruton's tyrosine kinase inhibitor M7583 in patients with B-cell malignancies. Leukemia & lymphoma. 62 (10), pp. 2392-2399. [Online]. 
  
Back to record